United States Pharmacopeia inks deal for life science consultancy

United States Pharmacopeia (USP), an independent, scientific nonprofit organization, has acquired Pharmatech Associates, Inc., a global consultancy for the life sciences industry. The new deal, officials say, enables USP to further expand on its objective of providing access to medicines by extending services that help manufacturers meet global quality standards across the drug and product lifecycle.

The global pharma supply chain consists of a vast marketplace of manufacturers, suppliers and distributors. In order to reinforce that supply chain, a multi-faceted approach is needed, USP contends. Pharmatech—whose employees will continue its day-to-day operations independent of USP—helps manufacturers meet their global regulatory requirements to bring products to market, scale up manufacturing, manage quality control and improve quality problems in an ever-changing landscape.

“The drug recalls we’ve seen in recent years and the supply chain challenges underscored by the Covid-19 pandemic have raised concerns about ongoing quality and safety issues,” says Ronald T. Piervincenzi, PhD, USP’s CEO. “This announcement positions us to continue to strengthen the supply chain and extend our many years of collaborating with global regulators and manufacturers to ensure the quality of medicines, as we have done with our donor-funded work and ingredient verification services for API[s] and excipients.”